EUCTR2004-005012-80-FI进行中（未招募）不适用
Double-blind, multicenter, randomized, placebo-controlled, parallel-group study to investigate the effect of Creon 25 000 Minimicrospheres on body mass index (BMI) in patients after gastrectomy.
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •*Signed informen consent. *Male or female at least 18 years old. *Patients with total or subtotal (Roux-en-Y anastomosis) gastrctomy. *Negative pregnancy test during prestudy. *Women with child-bearing potential must be using a medically acceptable method of birth control throughout the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •*Evidence of severe cardiovascular, respiratory, urogenital, gastrointestinal/hepatic, hematologic/immunologic, HEENT, dermatologic/connective tissue, muscoskeletal, metabolic/nutritional, endocrine, neurologic/psychiatric diseases, allergy or major surgery or other relevant diseases as revealed by history, physical examination and/or laboratory assessments which might limit participation in or completion of the study. *Sign of progressive tumours including metastasis. *Complications after gastrectomy which temporarily lead ti insufficient per oral nutrition. *Known allergy of pancreatin. *Known diagnosis of pancreatic exocrine insufficiency due to e.g. chronic pancreatitis or cystic fibrosis or pancreatectomy. *Any type of chronic organic intestinal disease, e.g. Morbus Crohn, Colitis ulcerosa. *Intake of an experimental drug within 4 weeks prior to entry into the study. *Excessive alcohol or drug abuse. *Unwilligness to participate and/or signed informed consent. *Suspected non-compliance or non cooperation. *Any other lack of fitness, in the investigator´s opinion, to participate in or to complete the tudy.
研究者
相似试验
已完成
不适用
Efficacy of Aripiprazole in Combination with Valproate or Lithium in the Treatment of Mania in Patients with Bipolar I Disorder Partially Nonresponsive to Valproate or Lithium MonotherapyPER-006-05BRISTOL MYERS SQUIBB COMPANY,
进行中（未招募）
不适用
Multicenter, double-blind, randomized, placebo-controlled, dose ranging phase 2 study to investigate efficacy, safety, tolerability and pharmacokinetics of the DPPIV inhibitor RO0730699 in patients with type 2 diabetes - NAEUCTR2004-004528-11-LVF. Hoffmann-La Roche Ltd250
已完成
3 期
Clinical trial developed at various hospitals where each patient randomly receive in parallel groups either placebo or treatment. Nor patients or investigators will know what the patient it's being given. This clinical trial evaluates efficacy and safety of the immunotherapy with allergen "Cup a 1" (major protein in Cupressus arizónica) in patients with allergic rhinoconjunctivitis with or without asthma sensitized to Cupressaceae pollenAllergic rhinoconjunctivitis2024-519527-14-00Diater Laboratorio De Diagnostico Y Aplicaciones Terapeuticas S.A.150
进行中（未招募）
1 期
Multicenter, double-blind, randomized, placebo-controlled, parallel-group study to assess the efficacy, safety and tolerability of tezosentan in patients with pre-operative pulmonary hypertension, due to left heart disease, undergoing cardiac surgeryCardiac Surgery, Separation from cardiopulmonary bypassMedDRA version: 9.1Level: LLTClassification code 10063082Term: Acute right ventricular failureEUCTR2006-002907-15-SKActelion Pharmaceuticals Ltd270
进行中（未招募）
不适用
Multicenter, double-blind, randomized, placebo-controlled, parallel-group study to assess the efficacy, safety and tolerability of tezosentan in patients with pre-operative pulmonary hypertension, due to left heart disease, undergoing cardiac surgery - NDSeparation from cardiopulmonary by-passMedDRA version: 9.1Level: LLTClassification code 10039163Term: Right ventricular failureEUCTR2006-002907-15-ITActelion Pharmaceuticals LTD270